Recognise vasomotor and genitourinary manifestations of menopause, distinguish important mimics, and match systemic, local and non-hormonal treatment to the symptom domain and cancer history.
Vasomotor symptoms reflect instability of hypothalamic thermoregulation during changing oestrogen signalling. A flush is a sudden wave of heat, often with facial or upper-body erythema, sweating, palpitations and subsequent chill. Night sweats fragment sleep and can worsen concentration, mood and fatigue. Ask about onset, frequency, triggers, nocturnal awakening and effect on work or driving. The pattern is often recognisable, but fever, thyrotoxicosis, hypoglycaemia, panic, medication effects, malignancy and infection require consideration when episodes are prolonged, atypical or accompanied by systemic features.
Genitourinary syndrome of menopause is a collective anatomical and symptom diagnosis. Reduced oestrogen changes vulval and vaginal epithelium, connective tissue, blood flow and the lactobacillus-dominant environment. Patients may describe dryness, burning, itching, reduced lubrication, postcoital spotting, superficial dyspareunia, urgency, frequency, dysuria or repeated urinary infection. Symptoms tend to persist or progress rather than resolve spontaneously. Ask sensitively about sexual function, products used, continence, recurrent antibiotic exposure and whether pain prevents examination or penetration.
Declining and fluctuating follicular activity changes oestrogen feedback and thermoregulatory signalling, producing variable symptoms before and after the final menstrual period.
Vulval, vaginal, urethral and bladder-trigone tissues respond to reduced oestrogen through epithelial thinning, altered collagen, reduced vascularity and microbiome change.
Oophorectomy, chemotherapy, pelvic radiotherapy and endocrine cancer therapy can cause abrupt or profound deficiency, often with more sudden vasomotor and genitourinary effects.
Altered hypothalamic neurokinin signalling narrows temperature tolerance, so small core-temperature changes trigger vasodilation, sweating and a subsequent cooling response.
Reduced oestrogen decreases epithelial maturation, glycogen, elasticity and tissue perfusion, leading to dryness, friability, narrowing and pain with friction.
Loss of glycogen and lactobacilli raises vaginal pH and alters periurethral defences, contributing to irritation, urgency and susceptibility to recurrent bacterial infection.
Repeated painful contact can recruit protective pelvic-floor contraction and anticipatory fear, perpetuating dyspareunia after some tissue findings have improved.
A brief spreading sensation of heat with sweating, flushing, palpitations and sometimes a subsequent chill, especially when recurrent at night, is characteristic.
Dryness, burning, reduced elasticity, loss of rugae, pallor, petechiae and superficial pain support genitourinary syndrome when focal dermatosis or infection is absent.
Urgency, frequency, dysuria and recurrent lower urinary infection can arise from periurethral and vaginal oestrogen deficiency but still require appropriate urine assessment.
Reduced lubrication, introital narrowing and protective pelvic-floor overactivity can combine, so treatment may require local oestrogen, lubrication and skilled pelvic-floor rehabilitation.
Sustained fever, major weight loss, lymphadenopathy, tremor or continuously drenching sweat is atypical and should trigger investigation for another disorder.
Thyrotoxicosis, hypoglycaemia, infection, malignancy, mast-cell disease, panic and medicines can cause heat or sweating with a different duration and associated findings.
Candida, bacterial vaginosis, contact dermatitis, lichen sclerosus, erosive lichen planus and vulvodynia may coexist with dryness and need disease-specific examination.
Bacterial infection, stone, incomplete emptying, overactive bladder, bladder pain syndrome and urothelial cancer can present with urgency or dysuria.
Endometrial, cervical, vaginal or vulval cancer must be excluded when bleeding, discharge, ulceration, induration or a focal mass accompanies symptoms.
Repeated night sweats fragment sleep and can worsen fatigue, concentration, mood, occupational performance and driving safety.
Dryness, introital narrowing, microtrauma and guarding can make touch or penetration painful, affecting desire, relationships and examination tolerance.
Altered vaginal ecology and periurethral tissue can increase bacterial recurrence, antibiotic exposure and the risk of resistant organisms.
Assuming all bleeding, urinary symptoms or sweats are menopausal can postpone recognition of infection, endocrine disease, cardiovascular illness or cancer.
Systemic HRT may control flushes yet leave vaginal or urinary symptoms, so adding low-dose vaginal treatment is coherent rather than therapeutic duplication.
A moisturiser is used regularly to improve background hydration, whereas a lubricant is applied around sexual activity to reduce friction and microtrauma.
Low-dose vaginal oestrogen produces far less systemic exposure than systemic HRT, but breast-cancer decisions still acknowledge uncertainty and current endocrine therapy.
Unlike many vasomotor symptoms, genitourinary tissue changes commonly continue and symptoms often recur when effective local treatment is withdrawn.
Fragile tissue and reduced lubrication may provoke pelvic-floor guarding, so persistent dyspareunia can need rehabilitation after the mucosa is treated.
Treating every sweat as menopause without checking for fever, thyrotoxicosis, medication effects, malignancy or cardiopulmonary symptoms.
Expecting systemic HRT alone to resolve vaginal dryness, dyspareunia and recurrent urinary symptoms in every patient.
Repeating antibiotics for dysuria despite negative cultures and visible oestrogen-deficient tissue.
Withholding all vaginal oestrogen automatically after breast cancer instead of applying the NICE sequence and involving the breast team for aromatase inhibitors.
Adding systemic progestogen solely because a licensed low-dose vaginal-oestrogen product is used in someone with a uterus.
Offering commercial vaginal laser as established treatment outside a randomised controlled trial.
Your practice draft is saved in this browser.
A 53-year-old using well-tolerated systemic HRT has good control of hot flushes but persistent vaginal dryness and superficial dyspareunia. Examination supports genitourinary syndrome and shows no suspicious lesion. What is the most appropriate next treatment?
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes
Examination is not mandatory for every typical mild presentation, but becomes valuable with bleeding, discharge, focal pain, skin change, treatment failure or diagnostic uncertainty. Inspect the vulva for dermatosis, fissure, ulcer or mass; a consented speculum examination may show pale fragile epithelium, loss of rugae, petechiae or a narrowed introitus. Test urine when infection is plausible and obtain cultures for recurrent or atypical episodes. Vaginal infection, lichen sclerosus, contact dermatitis, vulvodynia, bladder pain syndrome and cancer can coexist with or mimic oestrogen deficiency.
Treat the dominant domain. Systemic HRT is the most effective established treatment for vasomotor symptoms when benefits outweigh risks. Menopause-specific CBT can reduce the burden and distress of flushes and improve associated sleep, whether used with HRT or without it. The 2026 NICE pathway adds fezolinetant for moderate to severe vasomotor symptoms when HRT is unsuitable. Routine SSRIs, SNRIs or clonidine are not first-line for vasomotor symptoms alone, although individually selected non-hormonal medicines may have a role after contraindications, comorbidity and interactions are assessed.
Local therapy is usually the most direct treatment for genitourinary symptoms. NICE recommends vaginal oestrogen, including for people already taking systemic HRT, with the formulation chosen by preference and ability: cream, gel, tablet, pessary or ring. Minimal systemic absorption means a progestogen is not normally required with licensed low-dose preparations. Moisturisers and lubricants can be used instead of or alongside it. If these approaches fail or are not tolerated, vaginal prasterone is an option; oral ospemifene is reserved for circumstances in which local treatment is impractical. Vaginal laser should be offered only within a randomised controlled trial.
Breast-cancer history changes the conversation rather than ending it. Begin with non-hormonal moisturiser or lubricant. If symptoms persist, NICE permits consideration of vaginal oestrogen after discussing recurrence risk and the uncertainty of direct evidence. Systemic exposure is minimal; in oestrogen-receptor-negative disease it is unlikely to increase recurrence, while in receptor-positive disease the effect is unknown. Tamoxifen blocks oestrogen receptors and may reduce a potential effect, but an aromatase inhibitor aims for profound oestrogen suppression, so ongoing symptoms during aromatase-inhibitor therapy should be managed collaboratively with the breast team.
Treat active vaginal infection first, investigate unexplained bleeding, review response and use breast-specialist discussion when required by cancer history or aromatase-inhibitor therapy.
Contraindications include unexplained bleeding, known, past or suspected breast cancer, oestrogen-dependent malignancy, untreated endometrial hyperplasia and current or previous venous thromboembolism. Review benefit and risk at least every six months; concomitant vaginal oestrogen or systemic hormone treatment is not recommended by the SmPC.
Contraindicated with current or previous venous thromboembolism, unexplained bleeding, suspected breast cancer or active breast-cancer treatment, suspected or active sex-hormone-dependent malignancy, or signs of endometrial hyperplasia. Check CYP interactions, investigate bleeding and reassess benefit and risk at least annually.